Taiwan To Order 900,000 Doses Of Relenza As Tamiflu Backstop
This article was originally published in PharmAsia News
Executive Summary
Taiwan's Cabinet has decided to have the government buy 900,000 doses of GlaxoSmithKline's Relenza (zanamivir) flu drug, now considered the most efficient H1N1 treatment. The Department of Health minister said the $20 million purchase would be on top of doses in route from local manufacturers of Roche's Tamiflu (oseltamivir). The minister said Relenza would be provided for medical personnel and others more prone to infection, among them people who have contracted the Tamiflu-resistant strain of H1N1 now spreading. The government plans to buy 2.5 million H1N1 vaccine doses when local drug makers begin making them. (Click here for more
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.